{"id":782528,"date":"2023-09-07T13:07:06","date_gmt":"2023-09-07T17:07:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/"},"modified":"2023-09-07T13:07:06","modified_gmt":"2023-09-07T17:07:06","slug":"nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/","title":{"rendered":"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LOS ANGELES, Sept.  07, 2023  (GLOBE NEWSWIRE) &#8212; Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.\u00a0 At this institutional event, Ilya Rachman and Gabriel Morris will plan on being available to meet institutional investors and potential strategic pharmaceutical partners.<\/p>\n<p>\u201cWe are delighted to present the clinical progress we are making with our CAR-T, NXC-201, at this premier healthcare conference,\u201d said Ilya Rachman MD PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, \u201cWe believe the addressable market of CAR-Ts today is limited by neurotoxicity, which restricts dosing to only 5% of U.S. hospitals. We are looking forward to addressing this neurotoxicity challenge, potentially allowing a far wider adoption of CAR-T therapy, as we work to advance the market\u2019s first potentially outpatient CAR-T, NXC-201.\u201d<\/p>\n<p>\n        <b>About Immix Biopharma, Inc.<\/b><br \/>\n        <br \/>Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology including CAR-T cell therapies and Tissue Specific Therapeutics (TSTx). Our lead CAR-T cell therapy asset, NXC-201, is being developed for relapsed\/refractory AL Amyloidosis and relapsed\/refractory multiple myeloma. Initial response rates of 92% and 100% have been observed from the Phase 1b\/2a NEXICART-1 (NCT04720313) study in patients with multiple myeloma and AL amyloidosis (February 9, 2023). NXC-201 is being developed by ImmixBio\u2019s subsidiary Nexcella, Inc and has the potential to be the world\u2019s first out-patient CAR-T. Our lead Tissue Specific Therapeutic (TSTx) asset, IMX-110, is in Phase 1b\/2a clinical trials as a monotherapy and in the IMMINENT-01 combination clinical trial with BeiGene\u2019s anti-PD-1 antibody tislelizumab (NCT05840835). IMX-110 has been awarded Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the FDA. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tVqdfhSuZS2UvfDhiBWTlEp4qK_GAON1-6hbkE4ZMWEzB4QBvL3iFyCvb76F_peW6GChao4gNFJtONQ57csEjw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.immixbio.com<\/u><\/a>. <\/p>\n<p>\n        <b>About Nexcella, Inc.<\/b><br \/>\n        <br \/>Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (NASDAQ:IMMX), is a Los Angeles, California based clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our lead candidate, next generation BCMA-targeted CAR-T NXC-201 for relapsed\/refractory multiple myeloma and relapsed\/refractory AL amyloidosis, has produced 92% and 100% response rates in each indication, respectively, as of February 9, 2023, across 58 patients. We believe NXC-201 has potential to be the world\u2019s first outpatient CAR-T. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KWtPtPwmGlrGF48HTrlG9RHRlJo0UuUkDBeAUzOmbPR3w0lBReVkX1H3SsPQkRAAk_jp8Ur8TOllwgEyvGYsRg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.nexcella.com<\/u><\/a><\/p>\n<p>\n        <b>Forward Looking Statements<\/b><br \/>\n        <br \/> This press release contains \u201cforward-looking statements.\u201d Forward-looking statements reflect our current view about future events. When used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cplan,\u201d or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results, continuing development of our product candidates, including development timelines, timing of FDA submissions and expected endpoints, long-term visions and strategies, evaluations and judgements and beliefs regarding potential efficacy and safety of our product candidates, future clinical development of our product candidates, including any implication that results or observations in initial data or earlier clinical trials will be representative of results or observations in later data or clinical trials, the expected timing of such results and the potential market size for our product candidates. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you, therefore, against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; that our product candidates may not realize the anticipated responses discussed in this release or that their development may suffer delays that materially and adversely affects future commercial viability; that the market for our product candidates may not grow at the rates anticipated or at all; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned, including: the uncertainties related to market conditions and other factors described more fully in the section entitled \u2018Risk Factors\u2019 in Immix Biopharma\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports subsequently filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and we specifically disclaim any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. <\/p>\n<p>\n        <b>Contacts<\/b><br \/>\n        <br \/>Mike Moyer<br \/>LifeSci Advisors<br \/>mmoyer@lifesciadvisors.com<\/p>\n<p>\n        <b>Company Contact<\/b><br \/>\n        <br \/>irteam@immixbio.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzVkYjVkZDEtMjA5Yy00ZTBmLTkzNGItNDgzYWU5MWMzY2VkLTUwMDA5ODEwNA==\/tiny\/Immix-Biopharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.\u00a0 At this institutional event, Ilya Rachman and Gabriel Morris will plan on being available to meet institutional investors and potential strategic pharmaceutical partners. \u201cWe are delighted to present the clinical progress we are making with our CAR-T, NXC-201, at this premier healthcare conference,\u201d said Ilya Rachman MD PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782528","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.\u00a0 At this institutional event, Ilya Rachman and Gabriel Morris will plan on being available to meet institutional investors and potential strategic pharmaceutical partners. \u201cWe are delighted to present the clinical progress we are making with our CAR-T, NXC-201, at this premier healthcare conference,\u201d said Ilya Rachman MD PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, &hellip; Continue reading &quot;Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-07T17:07:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference\",\"datePublished\":\"2023-09-07T17:07:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/\"},\"wordCount\":969,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/\",\"name\":\"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==\",\"datePublished\":\"2023-09-07T17:07:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/","og_locale":"en_US","og_type":"article","og_title":"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference - Market Newsdesk","og_description":"LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Immix Biopharma, Inc. (Nasdaq: IMMX) (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will be presented by Ilya Rachman, MD, PhD, and Gabriel Morris at the Healthcare Trailblazers Private Company Conference Thursday, October 26, 2023.\u00a0 At this institutional event, Ilya Rachman and Gabriel Morris will plan on being available to meet institutional investors and potential strategic pharmaceutical partners. \u201cWe are delighted to present the clinical progress we are making with our CAR-T, NXC-201, at this premier healthcare conference,\u201d said Ilya Rachman MD PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, &hellip; Continue reading \"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-07T17:07:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference","datePublished":"2023-09-07T17:07:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/"},"wordCount":969,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/","name":"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==","datePublished":"2023-09-07T17:07:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODA5NiM1ODAyNzU2IzUwMDA5ODEwNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nexcella-immix-biopharma-subsidiary-to-present-at-the-bank-of-america-2023-healthcare-trailblazers-private-company-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782528"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782528\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}